Biological Products, (No Diagnostic Substances) · SIC 2836

Odyssey Therapeutics, Inc.

ODTX

Watch

Latest revenue

as of

Latest net income

as of

Net margin

as of

Community sentiment

Where do you think ODTX is heading?

1 month
6 months
12 months
5 years
Sign in free to vote and see community sentiment

Keep private notes on ODTX — thesis, target price, catalysts to watch.

Visible only to you. Never shared. Never used to train AI.

Sign in to add your own notes

ODTX vs S&P 500 · rebased to 100

(S&P 500 +10.2% / yr) 6.6% total
Compare:
Early cycleMid cycleLate cycleRecession

Background shading marks the US business-cycle phase at each point in time — early, mid and late expansion, then recession— so you can see which economic backdrop each move happened in. Recessions are NBER-official; expansion sub-phases are ActaClear's editorial dating.

Lines:
Overlay:

Live market

delayed ≤15 min
$18.07
1.49%
Market cap
$867.7M
Enterprise value
$867.7M
P/E (trailing)
Forward P/E
P/B
Dividend yield
0.0%
52-wk high
$20.30
52-wk low
$15.35
Beta
Shares out
48.0M

What this company does

AI

Not yet available for ODTX.

Key risks

AI

Not yet available for ODTX.

4.6
of 10

ActaClear Score

Neutral
#145 of 166 in Biological Products, (No Diagnostic Substances)
+0.5 · 23d
Profitability·25%
Growth·15%
Value·20%
3.1
Quality·20%
Momentum·20%
6.1

Computed from 5 years of SEC fundamentals + latest market data, ranked within Biological Products, (No Diagnostic Substances) (166 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 27, 2026.